{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:52:29Z","timestamp":1778871149189,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3520,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s13311-013-0215-4","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T11:33:18Z","timestamp":1379331198000},"page":"161-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Treatment of Tourette Syndrome"],"prefix":"10.1016","volume":"11","author":[{"given":"Roger M.","family":"Kurlan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1007\/s13311-013-0215-4_bib1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/mds.21599","article-title":"Malignant Tourette syndrome","volume":"22","author":"Cheung","year":"2007","journal-title":"Movement Disord"},{"issue":"6","key":"10.1007\/s13311-013-0215-4_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/mds.23618","article-title":"Tourette syndrome: Evolving concepts","volume":"26","author":"Jankovic","year":"2011","journal-title":"Movement Disord"},{"issue":"1","key":"10.1007\/s13311-013-0215-4_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1073858412444466","article-title":"Tic Disorders: What Happens in the Basal Ganglia?","volume":"19","author":"Bronfeld","year":"2013","journal-title":"Neuroscientist"},{"issue":"3","key":"10.1007\/s13311-013-0215-4_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biopsych.2007.12.009","article-title":"Corticospinal system excitability at rest is associated with tic severity in Tourette syndrome","volume":"64","author":"Orth","year":"2008","journal-title":"Biol Psychiat"},{"issue":"1","key":"10.1007\/s13311-013-0215-4_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/2013\/984836","article-title":"Premonitory urges and sensorimotor processing in Tourette syndrome","volume":"27","author":"Rajagopal","year":"2013","journal-title":"Behav Neurol"},{"issue":"3","key":"10.1007\/s13311-013-0215-4_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.22206","article-title":"Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome","volume":"518","author":"Kataoka","year":"2010","journal-title":"The J Compar Neurol"},{"issue":"37","key":"10.1007\/s13311-013-0215-4_bib7","doi-asserted-by":"crossref","first-page":"13307","DOI":"10.1073\/pnas.0502624102","article-title":"Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome","volume":"102","author":"Kalanithi","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1007\/s13311-013-0215-4_bib8","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/brain\/aws104","article-title":"Widespread abnormality of the \u03b3-aminobutyric acid-ergic system in Tourette syndrome","volume":"135","author":"Lerner","year":"2012","journal-title":"Brain"},{"issue":"19","key":"10.1007\/s13311-013-0215-4_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","article-title":"Behavior therapy for children with Tourette disorder","volume":"303","author":"Piacentini","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1007\/s13311-013-0215-4_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment","volume":"20","author":"Roessner","year":"2011","journal-title":"Eur Child Adolesc Psychiat."},{"issue":"2","key":"10.1007\/s13311-013-0215-4_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","article-title":"Contemporary Assessment and Pharmacotherapy of Tourette Syndrome","volume":"3","author":"Scahill","year":"2006","journal-title":"NeuroRX"},{"key":"10.1007\/s13311-013-0215-4_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1212\/WNL.52.4.874","article-title":"Short-term versus longer term pimozide therapy in Tourette's syndrome","volume":"52","author":"Tourette's Syndrome Study Group","year":"1999","journal-title":"Neurology"},{"issue":"13","key":"10.1007\/s13311-013-0215-4_bib13","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/mds.23894","article-title":"Does Tourette syndrome prevent tardive dyskinesia?","volume":"26","author":"M\u00fcller-Vahl","year":"2011","journal-title":"Movement Disord"},{"key":"10.1007\/s13311-013-0215-4_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J Clin Psychopharm."},{"key":"10.1007\/s13311-013-0215-4_bib15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"69","author":"Scahill","year":"2003","journal-title":"Neurology."},{"issue":"1","key":"10.1007\/s13311-013-0215-4_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.23402","article-title":"Tardive dyskinesia and other movement disorders secondary to aripiprazole","volume":"26","author":"Pe\u00f1a","year":"2011","journal-title":"Movement Disord"},{"key":"10.1007\/s13311-013-0215-4_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and ADHD","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatry."},{"key":"10.1007\/s13311-013-0215-4_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","article-title":"Clonidine treatment of Gilles de la Tourette syndrome","volume":"48","author":"Leckman","year":"1991","journal-title":"Arch Gen Psychiatry."},{"issue":"7","key":"10.1007\/s13311-013-0215-4_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","article-title":"Tourettes Syndrome and Role of Tetrabenazine: Review and Personal Experience","volume":"28","author":"Porta","year":"2008","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1007\/s13311-013-0215-4_bib20","first-page":"9","article-title":"Tetrabenazine in the treatment of Tourette syndrome","volume":"5","author":"Kenney","year":"2007","journal-title":"J Ped Neurol"},{"issue":"5","key":"10.1007\/s13311-013-0215-4_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/21678707.2013.787358","article-title":"Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications","volume":"1","author":"Jimenez-Shahed","year":"2013","journal-title":"Expert Opinion on Orphan Drugs"},{"issue":"1","key":"10.1007\/s13311-013-0215-4_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2010","journal-title":"J Neurol Neurosur Ps"},{"key":"10.1007\/s13311-013-0215-4_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.24919","article-title":"Pramipexole for TS Trial Investigators. A multi-center randomized placebo-controlled trial of pramipexole in Tourette's syndrome","volume":"27","author":"Kurlan","year":"2012","journal-title":"Movement Disord"},{"issue":"8","key":"10.1007\/s13311-013-0215-4_bib24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","article-title":"Botulinum toxin in the treatment of tics","volume":"57","author":"Kwak","year":"2000","journal-title":"Arch Neurol"},{"issue":"19","key":"10.1007\/s13311-013-0215-4_bib25","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review)","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-013-0215-4_bib26","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3171\/JNS-07\/11\/1004","article-title":"Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome","volume":"107","author":"Maciunas","year":"2007","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1007\/s13311-013-0215-4_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jnnp.2006.104067","article-title":"Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation","volume":"79","author":"Servello","year":"2008","journal-title":"J Neurol Neurosur Ps"},{"issue":"4","key":"10.1007\/s13311-013-0215-4_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000337776","article-title":"Deep brain stimulation for Tourette syndrome: target selection","volume":"90","author":"Viswanathan","year":"2012","journal-title":"Stereotactic and Functional Neurosurgery"},{"key":"10.1007\/s13311-013-0215-4_bib29","first-page":"953","article-title":"Treatment of ADHD in children with Tourette's syndrome (TACT Trial)","volume":"48","author":"Tourette's Syndrome Study Group","year":"2000","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1007\/s13311-013-0215-4_bib30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/chi.0b013e31805c0860","article-title":"Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder","volume":"46","author":"Gadow","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1007\/s13311-013-0215-4_bib31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","article-title":"Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders","volume":"65","author":"Allen","year":"2005","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0215-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301646X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301646X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0215-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:53Z","timestamp":1761808073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301646X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S187874792301646X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0215-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Tourette Syndrome","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0215-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}